Abstract
Cocaine and amphetamine are psychostimulant drugs that are illicitly used; they affect sensory perception by targeting the neurotransmitter: sodium symporters (NSS) at the synapses between neurons. They both increase the concentration of the neurotransmitter in the synaptic cleft but by different means.
The physiological role of NSS is the reuptake of their endogenous substrate. For this task, they exploit the pre-existing sodium-gradient across the cellular membrane that is maintained by the activity of the sodium:potassium pump. This reuptake process terminates synaptic transmission because the neurotransmitter is removed from the synaptic cleft — and its action on pre- and postsynaptic receptor molecules is stopped.
Amphetamines induce the reverse operation of distinct NSS family members, whereas cocaine merely inhibits the same transporters and thereby blocks the reuptake of neurotransmitter. These effects, although completely different in molecular mechanism, lead to an increase in the synaptic concentration of non-exocytotically released neurotransmitters. While these actions have long been appreciated, the underlying mechanistic details have been surprisingly difficult to understand. The advent of a crystal structure of a prokaryotic NSS protein and the concomitant development of homology models for eukaryotic NSS family members generated novel insights into the structure-function relationships of this clinically relevant class of transporters. Ultimately, we hope to understand the effects of amphetamines and cocaine on a molecular level to elucidate their profound effects on sensory perception.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Amara SG, Kuhar MJ (1993) Neurotransmitter transporters: recent progress. Annu Rev Neurosci 16: 73–93
Amara SG, Sonders MS (1998) Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend 51: 87–96
Axelrod J, Whitby LG, Hertting G (1961) Effect of psychotropic drugs on the uptake of 3H-Norepinephrine by tissues. Science 133: 383–384
Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K, Newman AH, Javitch JA, Weinstein H, Gether U, Loland CJ (2008) The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 11: 780–789
Beuming T, Shi L, Javitch JA, Weinstein H (2006) A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/ Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Mol Pharmacol 70: 1630–1642
Biel JH, Bopp BA (1978) Amphetamines: structure-activity relationships. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology: psychostimulants. pp 1–40, Plenum, New York
Blakely RD, Berson HE, Fremeau-RTJ, Caron MG, Peek MM, Prince HK, Bradley CC (1991) Cloning and expression of a functional serotonin transporter from rat brain. Nature 354: 66–70
Bönisch H (1984) The transport of (+)-amphetamine by the neuronal noradrenaline carrier. Naunyn Schmiedebergs Arch Pharmacol 327: 267–272
Bönisch H (1986) The role of co-transported sodium in the effect of indirectly acting sympathomimetic amines. Naunyn Schmiedebergs Arch Pharmacol 332: 135–141
Bönisch H, Trendelenburg U (1989) The mechanism of action of indirectly acting sympathomimetic amines. In: Trendelenburg U, Weiner N (eds) Handbook of Experimental Pharmacology: Catecholamines. pp 247–277, Springer, Berlin, Hamburg, New York
Bruss M, Hammermann R, Brimijoin S, Bonisch H (1995) Antipeptide antibodies confirm the topology of the human norepinephrine transporter. J Biol Chem 270: 9197–9201
Burn JH, Rand MJ (1958) The action of sympathomimetic amines in animals treated with reserpine. J Physiol 144: 314–336
Carvelli L, McDonald PW, Blakely RD, DeFelice LJ (2004) Dopamine transporters depolarize neurons by a channel mechanism. Proc Natl Acad Sci U S A 101: 16046–16051
Chen N, Reith ME (2000) Structure and function of the dopamine transporter. Eur J Pharmacol 405: 329–339
Chen R, Furman CA, Zhang M, Kim MN, Gereau RW, Leitges M, Gnegy ME (2009) Protein kinase Cbeta is a critical regulator of dopamine transporter trafficking and regulates the behavioral response to amphetamine in mice. J Pharmacol Exp Ther 328: 912–920
Cinquanta M, Ratovitski T, Crespi D, Gobbi M, Mennini T, Simantov R (1997) Carrier-mediated serotonin release induced by d-fenfluramine: studies with human neuroblastoma cells transfected with a rat serotonin transporter. Neuropharmacology 36: 803–809
Davis ME, Patrick RL (1990) Diacylglycerol-induced stimulation of neurotransmitter release from rat brain striatal synaptosomes. J Neurochem 54: 662–668
Desai RI, Kopajtic TA, Koffarnus M, Newman AH, Katz JL (2005) Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25: 1889–1893
Egana LA, Cuevas RA, Baust TB, Parra LA, Leak RK, Hochendoner S, Pena K, Quiroz M, Hong WC, Dorostkar MM, Janz R, Sitte HH, Torres GE (2009) Physical and functional interaction between the dopamine transporter and the synaptic vesicle protein synaptogyrin-3. J Neurosci 29: 4592–4604
Erreger K, Grewer C, Javitch JA, Galli A (2008) Currents in response to rapid concentration jumps of amphetamine uncover novel aspects of human dopamine transporter function. J Neurosci 28: 976–989
Eshleman AJ, Henningsen RA, Neve KA, Janowsky A (1994) Release of dopamine via the human transporter. Mol Pharmacol 45: 312–316
Ewing AG, Stein TS, Lau YY (1992) Analytical chemistry in microenvironments: single nerve cells. Accts Chem Res 440–447
Farhan H, Freissmuth M, Sitte HH (2006) Oligomerization of neurotransmitter transporters: a ticket from the endoplasmic reticulum to the plasma membrane. Handb Exp Pharmacol 233–249
Farhan H, Korkhov VM, Paulitschke V, Dorostkar MM, Scholze P, Kudlacek O, Freissmuth M, Sitte HH (2004) two discontinuous segments in the carboxy terminus are required for membrane targeting of the rat GABA transporter-1 (GAT1). J Biol Chem 279: 28 553–28 563
Farhan H, Reiterer V, Korkhov VM, Schmid JA, Freissmuth M, Sitte HH (2007) concentrative export from the endoplasmic reticulum of the gamma-aminobutyric acid transporter 1 requires binding to SEC24D. J Biol Chem 282: 7679–7689
Farhan H, Reiterer V, Kriz A, Hauri HP, Pavelka M, Sitte HH, Freissmuth M (2008) Signal-dependent export of GABA transporter 1 from the ER-golgi intermediate compartment is specified by a Cterminal motif. J Cell Sci 121: 753–761
Fischer JF, Cho AK (1979) Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther 208: 203–209
Fishkes H, Rudnick G (1982) Bioenergetics of serotonin transport by membrane vesicles derived from platelet dense granules. J Biol Chem 257: 5671–5677
Fjorback AW, Pla P, Muller HK, Wiborg O, Saudou F, Nyengaard JR (2009) Serotonin transporter oligomerization documented in rn46 a cells and neurons by sensitized acceptor emission FRET and fluorescence lifetime imaging microscopy. Biochem Biophys Res Commun 380: 724–728
Fleckenstein A, Burn JH (1953) The effect of denervation on the action of sympathomimetic amines on the nictitating membrane. Br J Pharmacol Chemother 8: 69–78
Fog JU, Khoshbouei H, Holy M, Owens WA, Vaegter CB, Sen N, Nikandrova Y, Bowton E, McMahon DG, Colbran R J, Daws L C, Sitte HH, Javitch JA, Galli A, Gether U (2006) Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51: 417–429
Forrest LR, Zhang YW, Jacobs MT, Gesmonde J, Xie L, Honig BH, Rudnick G (2008) Mechanism for alternating access in neurotransmitter transporters. Proc Natl Acad Sci USA 105: 10 338–10 343
Foster JD, Pananusorn B, Vaughan RA (2002) Dopamine transporters are phosphorylated on N-terminal serines in rat striatum. J Biol Chem 277: 25 178–25 186
Furchgott RF, Kirpekar SM, Rieker M, Schwab A (1963) Actions and interactions of norepinephrine, tyramine and cocaine on aortic strips of rabbit and left atria of guinea pig and cat. J Pharmacol Exp Ther 142: 39–58
Giambalvo CT (1992 a) Protein kinase C and dopamine transport-1. effects of amphetamine in vivo. Neuropharmacology 31: 1201–1210
Giambalvo CT (1992 b) Protein kinase C and dopamine transport-2. effects of amphetamine in vitro. Neuropharmacology 31: 1211–1222
Giambalvo CT (2003) Differential effects of amphetamine transport vs. dopamine reverse transport on particulate pkc activity in striatal synaptoneurosomes. Synapse 49: 125–133
Giros B, el Mestikawy S, Bertrand L, Caron MG (1991) Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett 295: 149–154
Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606–612
Glowinski J, Axelrod J (1965) Effect of drugs on the uptake, release, and metabolism of H3-norepinephrine in the rat brain. J Pharmacol Exp Ther 149: 43–49
Gnegy ME (2003) the effect of phosphorylation on amphetamine-mediated outward transport. Eur J Pharmacol 479: 83–91
Gnegy ME, Khoshbouei H, Berg K A, Javitch JA, Clarke WP, Zhang M, Galli A (2004) Intracellular Ca2+ regulates amphetamine-induced dopamine efflux and currents mediated by the human dopamine transporter. Mol Pharmacol 66: 137–143
Gobbi M, Funicello M, Gerstbrein K, Holy M, Moya PR, Sotomayor R, Forray MI, Gysling K, Paluzzi S, Bonanno G, Reyes-Parada M, Sitte HH, Mennini T (2008) N,N-dimethyl-thioamphetamine and methyl-thioamphetamine, two non-neurotoxic substrates of 5-HT transporters, have scant in vitro efficacy for the induction of transportermediated 5-HT release and currents. J Neurochem 105: 1770–1780
Gobbi M, Mennini T, Garattini S (1997) Mechanism of neurotransmitter release induced by amphetamine derivatives: pharmacological and toxicological aspects. Current Topics in Pharmacology 3: 217–227
Gobbi M, Moia M, Pirona L, Ceglia I, Reyes-Parada M, Scorza C, Mennini T (2002) p-methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro. J Neurochem 82: 1435–1443
Gorentla BK, Moritz AE, Foster JD, Vaughan RA (2009) Proline-directed phosphorylation of the dopamine transporter N-terminal domain. Biochemistry 48: 1067–1076
Granas C, Ferrer J, Loland CJ, Javitch JA, Gether U (2003) N-terminal truncation of the dopamine transporter abolishes phorbol ester-and substance P receptor-stimulated phosphorylation without impairing transporter internalization. J Biol Chem 278: 4990–5000
Guastella J, Nelson N, Nelson H, Czyzyk L, Keynan S, Miedel MC, Davidson N, Lester HA, Kanner BI (1990) Cloning and expression of a rat brain GABA Transporter. Science 249: 1303–1306
Hastrup H, Karlin A, Javitch JA (2001) Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment. Proc Natl Acad Sci U S A 98: 10 055–10 060
Hilgemann DW, Lu CC (1999) GAT1 (GABA:Na+:Cl-) cotransport function. database reconstruction with an alternating access model. J Gen Physiol 114: 459–475
Huang X, Zhan CG (2007) How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation. Biophys J 93: 3627–3639
Humphreys CJ, Wall SC, Rudnick G (1994) Ligand binding to the serotonin transporter: equilibria, kinetics, and ion dependence. Biochemistry 33: 9118–9125
Indarte M, Madura JD, Surratt CK (2008) Dopamine transporter comparative molecular modeling and binding site prediction using the LeuT(aa) leucine transporter as a template. Proteins 70: 1033–1046
Iversen L (2000) Neurotransmitter transporters: fruitful targets for cns drug discovery. Mol Psychiatry 5: 357–362
Iversen LL (1971) Role of transmitter uptake mechanisms in synaptic neurotransmission. Br J Pharmacol 41: 571–591
Jardetzky O (1966) Simple allosteric model for membrane pumps. Nature 211: 969–970
Javitch JA, Blaustein RO, Snyder SH (1984) [3H]Mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mol Pharmacol 26: 35–44
Javitch JA, D’Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 — tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173–2177
Jess U, Betz H, Schloss P (1996) The membranebound rat serotonin transporter, SERT1, is an oligomeric protein. FEBS Lett 394: 44–46
Jones SR, Gainetdinov RR, Wightman RM, Caron MG (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18: 1979–1986
Jones SR, Joseph JD, Barak LS, Caron MG, Wightman RM (1999) Dopamine neuronal transport kinetics and effects of amphetamine. J Neurochem 73: 2406–2414
Jorgensen AM, Tagmose L, Jorgensen AM, Topiol S, Sabio M, Gundertofte K, Bogeso KP, Peters GH (2007) Homology modeling of the serotonin transporter: insights into the primary escitalopram-binding site. ChemMedChem 2: 815–826
Just H, Sitte HH, Schmid JA, Freissmuth M, Kudlacek O (2004) Identification of an additional interaction domain in transmembrane domains 11 and 12 that supports oligomer formation in the human serotonin transporter. J Biol Chem 279: 6650–6657
Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A (2005) Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A 102: 3495–3500
Kalivas PW, Volkow ND (2005) The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162: 1403–1413
Kantor L, Gnegy ME (1998) Protein kinase c inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J Pharmacol Exp Ther 284: 592–598
Kantor L, Hewlett GH, Gnegy ME (1999) Enhanced amphetamine-and k+-mediated dopamine release in rat striatum after repeated amphetamine: differential requirements for Ca2+-and calmodulin-dependent phosphorylation and synaptic vesicles. J Neurosci 19: 3801–3808
Kantor L, Hewlett G H, Park YH, Richardson-Burns SM, Mellon MJ, Gnegy ME (2001) Protein kinase C and intracellular calcium are required for amphetamine-mediated dopamine release via the norepinephrine transporter in undifferentiated PC12 cells. J Pharmacol Exp Ther 297: 1016–1024
Kazanietz MG, Caloca MJ, Aizman O, Nowicki S (2001) Phosphorylation of the catalytic subunit of rat renal Na+, K+-ATPase by classical PKC isoforms. Arch Biochem Biophys 388: 74–80
Khoshbouei H, Sen N, Guptaroy B, Johnson L, Lund D, Gnegy ME, Galli A, Javitch JA (2004) N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2:E78
Khoshbouei H, Wang H, Lechleiter JD, Javitch JA, Galli A (2003) Amphetamine-induced dopamine efflux. a voltage-sensitive and intracellular Na+-dependent mechanism. J Biol Chem 278: 12 070–12 077
Kilic F, Rudnick G (2000) Oligomerization of serotonin tranporter and its functional consequences. Proc Natl Acad Sci U SA 97: 106–3111
Kocabas AM, Rudnick G, Kilic F (2003) Functional consequences of homo-but not hetero-oligomerization between transporters for the biogenic amine neurotransmitters. J Neurochem 85: 1513–1520
Korkhov VM, Holy M, Freissmuth M, Sitte HH (2006) The conserved glutamate (Glu136) in transmem-brane domain 2 of the serotonin transporter is required for the conformational switch in the transport cycle. J Biol Chem 281: 13439–13448
Kuhar MJ, Ritz MC, Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14: 299–302
L’hirondel M, Cheramy A, Godeheu G, Glowinski J (1995) Effects of arachidonic acid on dopamine synthesis, spontaneous release, and uptake in striatal synaptosomes from the rat. J Neurochem 64: 1406–1409
Langston JW, Irwin I, Langston EB, Forno LS (1984) 1-methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 48: 87–92
Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K, Sitte HH, Newman AH, Katz JL, Gether U (2008) Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73: 813–823
Lu CC, Hilgemann DW (1999a) GAT1 (GABA:Na+:Cl-) cotransport function. kinetic studies in giant xenopus oocyte membrane patches. J Gen Physiol 114: 445–457
Lu CC, Hilgemann DW (1999 b) GAT1 (GABA:Na+:Cl-) cotransport function. steady state studies in giant xenopus oocyte membrane patches. J Gen Physiol 114: 429–444
Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, Kosten TR (2009) Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 66: 1116–1123
Masson J, Sagne C, Hamon M, el Mestikawy S (1999) Neurotransmitter transporters in the central nervous system. Pharmacol Rev 51: 439–464
Mazei-Robinson MS, Blakely RD (2006) ADHD and the dopamine transporter: are there reasons to pay attention? Handb Exp Pharmacol 373–415
Mazei-Robison MS, Bowton E, Holy M, Schmudermaier M, Freissmuth M, Sitte HH, Galli A, Blakely RD (2008) Anomalous dopamine release associated with a human dopamine transporter coding variant. J Neurosci 28: 7040–7046
Meinild AK, Sitte HH, Gether U (2004) Zinc Potentiates an Uncoupled Anion Conductance Associated With the Dopamine Transporter. J Biol Chem 279: 49 671–49 679.
Moron JA, Zakharova I, Ferrer J V, Merrill GA, Hope B, Lafer EM, Lin ZC, Wang J B, Javitch JA, Galli A, Shippenberg TS (2003) Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport apacity. J Neurosci 23: 8480–8488
Nelson N (1998) The family of Na+/Cl-neurotransmitter transporters. J Neurochem 71: 1785–1803
Nestler EJ (2005) Is there a common molecular pathway for addiction? Nat Neurosci 8: 1445–1449
Nirenberg MJ, Chan J, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM (1997) Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area. J Neurosci 17: 5255–5262
Pacholczyk T, Blakely RD, Amara SG (1991) Expression cloning of a cocaine-and antidepressantsensitive human noradrenaline transporter. Nature 350: 350–354
Pifl C, Agneter E, Drobny H, Reither H, Singer EA (1997) Induction by low Na+ or Cl-of cocaine sensitive carrier-mediated efflux of amines from cells transfected with the cloned human catecholamine transporters. Br J Pharmacol 121: 205–212
Pifl C, Agneter E, Drobny H, Sitte HH, Singer EA (1999) Amphetamine reverses or blocks the operation of the human noradrenaline transporter depending on its concentration: superfusion studies on transfected cells. Neuropharmacology 38: 157–165
Pifl C, Drobny H, Reither H, Hornykiewicz O, Singer EA (1995) Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol 47: 368–373
Pifl C, Singer EA (1999) Ion dependence of carriermediated release in dopamine or norepinephrine transporter-transfected cells questions the hypothesis of facilitated exchange diffusion. Mol Pharmacol 56: 1047–1054
Pozzan T, Gatti G, Dozio N, Vicentini LM, Meldolesi J (1984) Ca2+-dependent and-independent release of neurotransmitters from PC12 cells: a role for protein kinase C activation? J Cell Biol 99: 628–638
Ramamoorthy S, Blakely RD (1999) Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285: 763–766
Ramamoorthy S, Samuvel DJ, Buck ER, Rudnick G, Jayanthi LD (2007) Phosphorylation of threonine residue 276 is required for acute regulation of serotonin transporter by cyclic GMP. J Biol Chem 282: 11 639–11 647
Robertson SD, Matthies HJ, Galli A (2009) A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol 39: 73–80
Ross SB, Renyi AL (1966) Uptake of some tritiated sympathomimetic amines by mouse brain cortex slices in vitro. Acta Pharmacol Toxicol (Copenh) 24: 297–309
Roux MJ, Supplisson S (2000) Neuronal and glial glycine transporters have different stoichiometries. Neuron 25: 373–383
Rudnick G (2006) Structure/function relationship in serotonin transporter. In: Sitte HH, Freissmuth M (eds) Neurotransmitter transporters pp 59–73, Springer-Verlag, Berlin Heidelberg
Rudnick G, Clark J (1993) From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144: 249–263
Rudnick G, Wall SC (1992) p-chloroamphetamine induces serotonin release through serotonin transporters. Biochemistry 31: 6710–6718
Saier MH Jr., Tran CV, Barabote RD (2006) TCDB: the transporter classification database for membrane transport protein analyses and information. Nucleic Acids Res 34:D181–D186
Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 97: 6850–6855
Schmid JA, Scholze P, Kudlacek O, Freissmuth M, Singer EA, Sitte HH (2001) Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. J Biol Chem 276: 3805–3810
Scholze P, Freissmuth M, Sitte HH (2002 a) Mutations within an intramembrane leucine heptad repeat disrupt oligomer formation of the rat GABA transporter 1. J Biol Chem 277: 43 682–43 690
Scholze P, Norregaard L, Singer EA, Freissmuth M, Gether U, Sitte HH (2002 b) The role of zinc ions in reverse transport mediated by monoamine Transporters. J Biol Chem 277: 21 505–21 513
Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH (2000) Transporter-Mediated Release: A superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther 293: 870–878
Seidel S, Singer EA, Just H, Farhan H, Scholze P, Kudlacek O, Holy M, Koppatz K, Krivanek P, Freissmuth M, Sitte HH (2005) Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action. Mol Pharmacol 67: 140–151
Seiden LS, Sabol KE, Ricaurte GA (1993) Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33: 639–677
Sen N, Shi L, Beuming T, Weinstein H, Javitch JA (2005) A pincer-like configuration of TM2 in the human dopamine transporter is responsible for indirect effects on cocaine binding. Neuropharmacology 49: 780–790
Shi L, Quick M, Zhao Y, Weinstein H, Javitch JA (2008) The mechanism of a neurotransmitter: sodium symporter-inward release of Na+ and substrate is triggered by substrate in a second binding site. Mol Cell 30: 667–677
Singh SK (2008) LeuT: a prokaryotic stepping stone on the way to a eukaryotic neurotransmitter transporter structure. Channels (Austin) 2: 380–389
Singh SK, Piscitelli CL, Yamashita A, Gouaux E (2008) A competitive inhibitor traps leut in an open-toout conformation. Science 322: 1655–1661
Sitte HH, Farhan H, Javitch JA (2004) Sodium-dependent neurotransmitter transporters: oligomerization as a determinant of transporter function and trafficking. Mol Interv 4: 38–47
Sitte HH, Freissmuth M (2003) Oligomer formation by Na+-Cl-coupled neurotransmitter transporters. Eur J Pharmacol 479: 229–236
Sitte HH, Hiptmair B, Zwach J, Pifl C, Singer EA, Scholze P (2001) Quantitative analysis of inward and outward transport rates in cells stably expressing the cloned human serotonin transporter: inconsistencies with the hypothesis of facilitated exchange diffusion. Mol Pharmacol 59: 1129–1137
Sitte HH, Huck S, Reither H, Boehm S, Singer EA, Pifl C (1998) Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J Neurochem 71: 1289–1297
Sitte HH, Scholze P, Schloss P, Pifl C, Singer EA (2000) Characterization of carrier-mediated release in human embryonic kidney 293 cells stably expressing the rat serotonin transporter: a superfusion study. J Neurochem 74: 1317–1324
Sitte HH, Singer EA, Scholze P (2002) Bi-directional transport of gaba in human embryonic kidney (HEK-293) cells stably expressing the rat GABA Transporter GAT-1. Br J Pharmacol 135: 93–102
Sorkina T, Doolen S, Galperin E, Zahniser NR, Sorkin A (2003) Oligomerization of dopamine transporters visualized in living cells by FRET microscopy. J Biol Chem 278: 28 274–28 283
Sulzer D, Sonders M S, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75: 406–433
Torres GE, Carneiro A, Seamans K, Fiorentini C, Sweeney A, Yao WD, Caron MG (2003 a) Oligomerization and trafficking of the human dopamine transporter. mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol Chem 278: 2731–2739
Torres GE, Gainetdinov RR, Caron MG (2003 b) Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 4: 13–25
Trendelenburg U, Langeloh A, Bönisch H (1987) Mechanism of action of indirectly acting sympathomimetic amines. Blood Vessels 24: 261–270
Wall SC, Gu H, Rudnick G (1995) Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol 47: 544–550
Wang D, Deken SL, Whitworth TL, Quick MW (2003) Syntaxin 1A inhibits GABA flux, efflux, and exchange mediated by the rat brain GABA transporter GAT1. Mol Pharmacol 64: 905–913
Wolfel R, Graefe KH (1992) Evidence for various tryptamines and related compounds acting as substrates of the platelet 5-hydroxytryptamine transporter. Naunyn Schmiedebergs Arch Pharmacol 345: 129–136
Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E (2005) Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters. Nature 437: 215–223
Zaczek R, Culp S, De SE (1991) Interactions of [3H] amphetamine with rat brain synaptosomes. II. active transport. J Pharmacol Exp Ther 257: 830–835
Zhu CB, Carneiro AM, Dostmann WR, Hewlett WA, Blakely RD (2005) P38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J Biol Chem 280: 15649–15658
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag/Wien
About this chapter
Cite this chapter
Weissensteiner, R. et al. (2012). Towards an understanding of the psychostimulant action of amphetamine and cocaine. In: Barth, F.G., Giampieri-Deutsch, P., Klein, HD. (eds) Sensory Perception. Springer, Vienna. https://doi.org/10.1007/978-3-211-99751-2_11
Download citation
DOI: https://doi.org/10.1007/978-3-211-99751-2_11
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-99750-5
Online ISBN: 978-3-211-99751-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)